Related Experiment Video
Updated: May 20, 2026

In vitro Assessment of Cardiac Reprogramming by Measuring Cardiac Specific Calcium Flux with a GCaMP3 Reporter
Published on: February 22, 2022
FHL2 binds calcineurin and represses pathological cardiac growth
Berdymammet Hojayev1, Beverly A Rothermel, Thomas G Gillette
1Department of Internal Medicine (Cardiology), University of Texas Southwestern Medical Center, Dallas, TX, USA.
Abstract:
Stress-induced hypertrophic growth of the heart predisposes the heart to arrhythmia, contractile dysfunction, and clinical heart failure. FHL2 (four-and-a-half LIM domain protein 2) is expressed predominantly in the heart, and inactivation of the gene coding for FHL2 leads to exaggerated responsiveness to adrenergic stress. Activation of calcineurin occurs downstream of β-adrenergic signaling and is required for isoproterenol-induced myocardial hypertrophy. Based on these facts, we hypothesized that FHL2 suppresses stress-induced activation of calcineurin. FHL2 is upregulated in mouse hearts exposed to isoproterenol, a β-adrenergic agonist, and isoproterenol-induced increases in the NFAT target genes RCAN1.4 and BNP were amplified significantly in FHL2 knockout (FHL2(-/-)) mice compared with levels in wild-type (WT) mice. To determine whether the effect of FHL2 on NFAT target gene transcript levels occurred at the level of transcription, HEK 293 cells and neonatal rat ventricular myocytes (NRVMs) were transfected with a luciferase reporter construct harboring the NFAT-dependent promoters of either RCAN1 or interleukin 2 (IL-2). Consistent with the in vivo data, small interfering RNA (siRNA) knockdown of FHL2 led to increased activation of these promoters by constitutively active calcineurin or the calcium ionophore ionomycin. Importantly, activation of the RCAN1 promoter by ionomycin, in control and FHL2 knockdown cells, was abolished by the calcineurin inhibitor cyclosporine, confirming the calcineurin dependence of the response. Overexpression of FHL2 inhibited activation of both NFAT reporter constructs. Furthermore, NRVMs overexpressing FHL2 exhibited reduced hypertrophic growth in response to constitutively active calcineurin, as measured by cell cross-sectional area and fetal gene expression. Finally, immunostaining in isolated adult cardiomyocytes revealed colocalization of FHL2 and calcineurin predominantly at the sarcomere and activation of calcineurin by endothelin-1-facilitated interaction between FHL2 and calcineurin. FHL2 is an endogenous, agonist-dependent suppressor of calcineurin.
Insights
Four-and-a-half LIM domain protein 2 (FHL2) suppresses stress-induced calcineurin activation in the heart. FHL2 deficiency exacerbates cardiac hypertrophy and dysfunction, highlighting its protective role against heart failure.
Area of Science:
- Cardiovascular Biology
- Molecular Cardiology
- Cellular Signaling
Background:
- Stress-induced cardiac hypertrophy predisposes the heart to arrhythmia, contractile dysfunction, and heart failure.
- Four-and-a-half LIM domain protein 2 (FHL2) is primarily expressed in the heart and its deficiency leads to heightened responses to adrenergic stress.
- Calcineurin activation, downstream of β-adrenergic signaling, is crucial for stress-induced myocardial hypertrophy.
Purpose of the Study:
- To investigate the hypothesis that FHL2 suppresses stress-induced calcineurin activation.
- To elucidate the role of FHL2 in regulating cardiac responses to adrenergic stress and hypertrophy.
Main Methods:
- In vivo studies using FHL2 knockout mice and isoproterenol stimulation to assess NFAT target gene expression.
- In vitro studies using HEK 293 cells and neonatal rat ventricular myocytes (NRVMs) with reporter gene assays to evaluate FHL2's effect on calcineurin/NFAT signaling.
- siRNA-mediated knockdown and overexpression of FHL2 to determine its functional role.
- Immunostaining in adult cardiomyocytes to examine FHL2 and calcineurin localization and interaction.
Main Results:
- FHL2 knockout mice exhibited amplified isoproterenol-induced increases in NFAT target genes RCAN1.4 and BNP.
- FHL2 knockdown enhanced calcineurin/NFAT promoter activity, while FHL2 overexpression inhibited it.
- FHL2 overexpression in NRVMs reduced hypertrophic growth in response to calcineurin activation.
- FHL2 and calcineurin colocalized in cardiomyocytes, and their interaction was facilitated by endothelin-1.
Conclusions:
- FHL2 acts as an endogenous suppressor of calcineurin activity in the heart.
- FHL2 plays a critical role in mitigating stress-induced cardiac hypertrophy and dysfunction.
- Targeting FHL2 may offer a therapeutic strategy for preventing or treating heart failure.
More Related Videos
09:16Suppression of Pro-fibrotic Signaling Potentiates Factor-mediated Reprogramming of Mouse Embryonic Fibroblasts into Induced Cardiomyocytes
Published on: June 3, 2018
13:13High Efficiency Differentiation of Human Pluripotent Stem Cells to Cardiomyocytes and Characterization by Flow Cytometry
Published on: September 23, 2014
Related Concept Videos
Calmodulin-dependent Signaling
The Ca2+-CaM complex does not have enzymatic activity by itself. Instead, the complex binds downstream target proteins, including membrane proteins or enzymes,...
Synthesis and Functions of Calcitonin
The exact mechanisms by which calcitonin operates in calcium homeostasis remain elusive, but its significance is evident in several vital...
Heart Failure II: Pathophysiology
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Hormones and Bone Tissue
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...
Antihypertensive Drugs: Action of Calcium Channel Blockers